無水イミペネム

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H315：皮膚刺激

  H319：強い眼刺激

  H335：呼吸器への刺激のおそれ

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

無水イミペネム 化学特性,用途語,生産方法

• 効能

  抗生物質, 細胞壁合成阻害薬

• 説明

  Imipenem is a chemically stable thienamycin derivative with an antibacterial activity that is broader in spectrum and of greater potency than most of the third generation cephalosporins. Combination with cilastatin, an inhibitor of renal brush-border dehydropeptidase-I, increases both urinary and plasma levels of imipenem.

• 化学的特性

  White Crystals

• 使用

  Carbapenem antibacterial.

• 抗菌性

  Imipenem shows potent activity against a wide range of Grampositive and Gram-negative aerobes and anaerobes, including many resistant to other agents.Concentrations (mg/L) inhibiting 50% of strains of other organisms are: Listeria monocytogenes, 0.03; Legionella pneumophila, 0.03; Enterococcus faecium, 4; Yersinia spp., 0.06. Mycobacterium fortuitum is inhibited by 6.25 mg/L. Imipenem is active against many Pseudomonas species, but not Sten. maltophilia. It is active against most anaerobes, with the exception of Cl. perfringens, which is only moderately susceptible. It is bactericidal at 2–4 times the MIC for most species, but some strains of Staph. aureus exhibit ‘tolerance’ . Bactericidal synergy with aminoglycosides, glycopeptides, fosfomycin and rifampicin (rifampin) has been observed against many strains of Staph. aureus and enterococci.
  Antibacterial activity is unaffected by the presence of cilastatin, which is itself devoid of antimicrobial activity.
  Imipenem is stable to hydrolysis by most serine β-lactamases, with the exception of the group 2f carbapenem-hydrolyzingenzymes hydrolyzingenzymes . Strains of B. fragilis, Aeromonas spp. and Sten. maltophilia can produce metallo-β-lactamases that hydrolyze the drug rapidly. These strains, in addition to occasional strains of enterobacteria, Acinetobacter baumannii and Ps. aeruginosa, show variable resistance to imipenem depending upon the level of carbapenem-hydrolyzing enzymes and the presence or absence of imipenem-specific porins. Efflux pumps also exist that may extrude imipenem from Gramnegative bacteria.

• 獲得抵抗性

  Some strains of Citrobacter, Enterobacter, Proteus vulgaris, Providencia, Ps. aeruginosa and Serratia spp. may be resistant to imipenem and other β-lactam agents, often because of the selection of stably derepressed mutants expressing high levels of group 1 β-lactamases coupled with decreased intracellular drug levels due to porin mutations or increased efflux.
  Induction of class 1 β-lactamases by imipenem in strains of Aeromonas, Pseudomonas and Serratia spp. is responsible for antagonism of β-lactamase-labile β-lactam agents in vitro. Imipenem resistance in Ps. aeruginosa can occur following selection of mutants that hyperproduce the group 1 cephalosporinase and which are also deficient in an outer membrane protein (OprD or D2) which specifically transports imipenem, but not cephalosporins or monobactams.

• 一般的な説明

  Thienamycin was found in the culture broth of Streptomyces cattleya by Merck Sharp & Dohme in 1976, as a very unstable substance. It has a unique carbapenem structure, like that of the olivanic acids found in S. olivaceus by Beecham Research Laboratories in 1979. Thienamycin shows excellent activity against a variety of pathogenic bacteria, including Pseudomonas aeruginosa. Its chemical stability has been improved by derivatization with the formimidoyl group, and its biological stability has been improved by combining it with cilastatin, an inhibitor of kidney dihydropeptidase. The combination drug imipenem – cilastatin is now under study to evaluate its clinical efficacy and safety.

• 臨床応用

  Lower respiratory tract infections
  Urinary tract infections (complicated and uncomplicated)
  Intra-abdominal infections
  Gynecological infections
  Bacterial septicemia
  Bone and joint infections
  Skin and skin structure infections
  Endocarditis
  Polymicrobial infections

• 副作用

  CNS effects such as confusional states and seizures have been reported, especially when recommended doses were exceeded, and in patients with renal failure or creatinine clearances of ≤20 mL/min/1.73 m2.
  Other reactions include phlebitis/thrombophlebitis (3.1%), nausea (2.0%), diarrhea (1.8%) and vomiting (1.5%).
  Increased hepatic enzymes may be seen in adults and children. Superinfection with Aspergillus, Candida and resistant Pseudomonas spp. have been described and pseudomembranous colitis has been reported.
  Patients with a history of hypersensitivity reactions to penicillins, cephalosporins or other β-lactam antibiotics should be treated cautiously with carbapenems.

無水イミペネム 上流と下流の製品情報

無水イミペネム 生産企業

Global(272)Suppliers

64221-86-9, 無水イミペネム キーワード